Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds

PURPOSE: Achieving good glycemic control in type 2 diabetes (T2DM) may require individualized pharmacological approaches. We aimed to compare direct healthcare costs in patients treated with empagliflozin (EMPA) compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilke, Thomas, Picker, Nils, Müller, Sabrina, Stürmlinger, Anna, Deiters, Barthold, Dittmar, Axel, Aberle, Jens, Gabler, Maximilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075907/
https://www.ncbi.nlm.nih.gov/pubmed/35531480
http://dx.doi.org/10.2147/CEOR.S357540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075907/
https://www.ncbi.nlm.nih.gov/pubmed/35531480
http://dx.doi.org/10.2147/CEOR.S357540

Ejemplares similares